BSNS WIRE) Centrex Advances Efforts to Launch SMD System for Viral and Bacte
ial Detection
Centrex Advances Efforts to Launch SMD System for Viral and Bacterial Detection
Health/Medical Writers / Business Editors
TULSA, Okla.--(BUSINESS WIRE)--CNEX--
Centrex, Inc. (OTCBB:CNEX) today announced that
Micronics, Inc., has advanced the development of an assay that
contains Centrex´s single molecule nucleic acid detection (" SMD" )
technology for application in a laboratory-on-a-card (" lab card" )
format. Micronics reported to Centrex that it has achieved this
important initial milestone which permits lysis and binding reactions
in the lab card format.
SMD technology, in combination with an easy-to-operate lab card
device and integrated reader, is expected to be responsive to the need
for rapid, user friendly and cost effective solutions for point-of-use
analyses of a variety of bacterial and viral organisms.
Centrex´s SMD technology was exclusively licensed from Los Alamos
National Laboratories, and offers important advantages over existing
DNA and RNA detection methods as well as culture-based test methods.
SMD technology eliminates the need for amplification of the target DNA
by recognizing the unique DNA or RNA fingerprint of the target
organism. This reduces the possibility of false positive and negative
test results - common concerns frequently identified with other test
procedures.
As a next step in the development process, Micronics is expected
to integrate the lysing/binding reactions together with SMD using a
biological stimulant, the spores of the bacteria Bacillus globigii.
Bacillus globigii prepared in this manner may be used safely to
simulate Bacillus anthracis (anthrax) spores in the DNA extraction and
binding experiments.
Centrex is focusing commercial efforts in the development of a
product that uses SMD as part of a simultaneous, multi-channel
detection system that is compact, fully automated and capable of
monitoring the presence of biological agents in air, food and water.
Potential additional applications for the SMD technology include
bioterrorism and Homeland Security, food and water processing, blood
supply screening, and general DNA/RNA testing.
Redmond, Washington-based Micronics provides custom lab card
design, development and prototypes systems. The proposed lab card for
the Centrex system is expected to include fully automated on-card
sample preparation, mixing, separation, and analysis. Reagent and
waste storage also are designed to be on card for ease of use and
disposal. Micronics is believed to offer the most sophisticated and
rapid lab card prototyping facility in the world today. For additional
information please visit www.micronics.net.
For more information call Ron Wheet at (843) 971-4848 or visit the
Centrex website at www.centrexcorporation.com.
This press release contains certain forward-looking statements. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Forward-looking statements in this document should be
evaluated together with the many uncertainties that affect our
business. Those uncertainties are discussed in the Company´s SEC
filings.
KEYWORD: OKLAHOMA
INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL MEDICAL MEDICAL DEVICES MEDICAL PRODUCT
SOURCE: Centrex, Inc.
CONTACT INFORMATION:
Centrex, Inc., Tulsa
Ron Wheet, 843-971-4848
Zurück
Weiter
